Hurley Capital’s Yarrow Bioscience YARW Stock Holding History

Hurley Capital’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$248	Hold	11	–	–	﹤0.01%	626
2026 Q2	$365	Hold	11	–	–	﹤0.01%	626
2026 Q1	$335	Hold	11	–	–	﹤0.01%	624
2025 Q4	$325	Buy	+11	New	+$221	﹤0.01%	554

Other funds holding YARW

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Monashee Investment Management Boston, Massachusetts $33.4M AUM 92.4% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

MB, Levis & Associates Center Valley, Pennsylvania $273M AUM 8.08% 1-Year Est. Return

Hurley Capital's YARW Position: Q3 2026 in Review

Hurley Capital held its Yarrow Bioscience (YARW) position steady in Q3 2026 at 11 shares worth $248. The position accounts for ﹤0.01% of the portfolio, ranked #626.

Hurley Capital first reported a position in YARW in Q4 2025 and has held it in 4 quarters since. The position peaked at $365 in Q2 2026. 8 funds tracked by Wall St. Rank hold YARW as of Q3 2026.

Hurley Capital held 11 shares of Yarrow Bioscience worth $248 as of Q3 2026.
Hurley Capital left its Yarrow Bioscience share count unchanged in Q3 2026.
Yarrow Bioscience made up ﹤0.01% of Hurley Capital's portfolio in Q3 2026, its #626 holding.
Hurley Capital first reported a position in Yarrow Bioscience in Q4 2025 and has held it in 4 quarters since.
Hurley Capital's Yarrow Bioscience position peaked at $365 in Q2 2026.
8 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q3 2026.

Based on Hurley Capital's 13F filing for Q3 2026, filed 5 Nov 2026.